Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warfarin dosing test

This article was originally published in The Gray Sheet

Executive Summary

Kimball Genetics joins the small number of labs performing pharmacogenetic tests for warfarin therapy with the launch of its Warfarin DoseAdvise June 5. The test, performed at Kimball's CLIA-certified lab in Denver, analyzes genes in blood or cheek cell samples to inform dosing of the common blood thinner. According to Kimball CEO Annette Taylor, FDA plans to revise warfarin product labeling to advocate genetic testing. Other labs offering warfarin dosing tests include Clinical Data (PGxPredict). Third Wave, which sells reagents for warfarin tests, is developing the Invader warfarin in vitro diagnostic (1"The Gray Sheet" March 6, 2006, p. 12)...

You may also be interested in...



Third Wave, Now An IVD Company, Is Banking On Personalized Medicine

Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel